Virus-like particles (VLPs) are multimeric nanostructures composed of one or more structural
proteins of a virus in the absence of genetic material. Having similar morphology to natural …

Virus-like particles (VLPs) are formed by the self-assembly of envelope and/or capsid
proteins from many viruses. In many cases such VLPs have structural characteristics and …

With very few adjuvants currently being used in marketed human vaccines, a critical need
exists for novel immunopotentiators and delivery vehicles capable of eliciting humoral …

Hepatitis B virus (HBV) infection is a world wide public health problem of major concern.
HBV infection may lead to chronic liver disease, including cirrhosis and hepatocellular …

The lack of an appropriate in vitro infection system for the major human pathogen hepatitis B
virus (HBV) has prevented a molecular understanding of the early infection events of HBV …

Current vaccines that provide protection against infectious diseases have primarily relied on
attenuated or inactivated pathogens. Virus‐like particles (VLPs), comprised of capsid …

Hepatitis B remains one of the major global health problems more than 40 years after the
identification of human hepatitis B virus (HBV) as the causative agent. A critical turning point …

Efficacy and safety of recombinant yeast-derived hepatitis B vaccines for prevention of
hepatitis B have been demonstrated unequivocally worldwide as reflected in reduction in …

Worldwide, two billion people have at some time been infected by hepatitis B virus, 370
millions suffer from chronic infection and around one million die each year from HBV-related …

Hepatitis B vaccines have now been available for over 20 years. The World Health
Organization has recommended that hepatitis B vaccination should be included in routine …